SSII supply chain intelligence for SS Innovations International, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ISRG | Intuitive Surgical, Inc. | 72% | Reciprocal relationship from ISRG graph: Reciprocal relationship from SSII graph: from a large number of suppliers from both within India and overseas and subject them to stringent quality specificat… |
| ISRG | Intuitive Surgical, Inc. | 72% | from a large number of suppliers from both within India and overseas and subject them to stringent quality specifications, inspections, and processes. Some of the components necessary for the assembl… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from SSII graph: from a large number of suppliers from both within India and overseas and subject them to stringent quality specificati… |
| JNJ | Johnson & Johnson | 72% | from a large number of suppliers from both within India and overseas and subject them to stringent quality specifications, inspections, and processes. Some of the components necessary for the assembl… |
| MDT | Medtronic plc | 72% | Reciprocal relationship from MDT graph: Reciprocal relationship from SSII graph: from a large number of suppliers from both within India and overseas and subject them to stringent quality specificati… |
| MDT | Medtronic plc | 72% | from a large number of suppliers from both within India and overseas and subject them to stringent quality specifications, inspections, and processes. Some of the components necessary for the assembl… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CUSTOMER-A | CUSTOMER-A | 90% | Details of customers which accounted for 10% or more of total revenues during the three months ended March 31, 2026, and March 31, 2025 and 10% or more of total accounts receivables as at March 31, 2… |
| CUSTOMER-B | CUSTOMER-B | 90% | Details of customers which accounted for 10% or more of total revenues during the three months ended March 31, 2026, and March 31, 2025 and 10% or more of total accounts receivables as at March 31, 2… |
| CUSTOMER-C | CUSTOMER-C | 90% | Details of customers which accounted for 10% or more of total revenues during the three months ended March 31, 2026, and March 31, 2025 and 10% or more of total accounts receivables as at March 31, 2… |
| CUSTOMER-D | CUSTOMER-D | 90% | Details of customers which accounted for 10% or more of total revenues during the three months ended March 31, 2026, and March 31, 2025 and 10% or more of total accounts receivables as at March 31, 2… |
| CUSTOMER-E | CUSTOMER-E | 90% | Details of customers which accounted for 10% or more of total revenues during the three months ended March 31, 2026, and March 31, 2025 and 10% or more of total accounts receivables as at March 31, 2… |
| CUSTOMER-CONTRACTS-THE-CO | CUSTOMER-CONTRACTS-THE-CO | 85% | e goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: ● Identification of a contract with a customer or placement of a purchase order … |
| ISRG | Intuitive Surgical, Inc. | 72% | after they receive their system. To date, substantially all of our sales have been in India, with one sale each in the United Arab Emirates, Ecuador, Nepal and Indonesia. Training and Customer Suppor… |
| ISRG | Intuitive Surgical, Inc. | 72% | Reciprocal relationship from ISRG graph: Reciprocal relationship from SSII graph: Reciprocal relationship from ISRG graph: Reciprocal relationship from SSII graph: after they receive their system. To… |
| JNJ | Johnson & Johnson | 72% | after they receive their system. To date, substantially all of our sales have been in India, with one sale each in the United Arab Emirates, Ecuador, Nepal and Indonesia. Training and Customer Suppor… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from SSII graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from SSII graph: after they receive their system. To d… |
| MDT | Medtronic plc | 72% | after they receive their system. To date, substantially all of our sales have been in India, with one sale each in the United Arab Emirates, Ecuador, Nepal and Indonesia. Training and Customer Suppor… |
| MDT | Medtronic plc | 72% | Reciprocal relationship from MDT graph: Reciprocal relationship from SSII graph: after they receive their system. To date, substantially all of our sales have been in India, with one sale each in the… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| SSII-DEBT-12754 | Warrants outstanding: 0.78 | 90% | xbrl warrant detail from xbrl 2023-12-31. |
| SSII-DEBT | Debt stack $13.8M | 90% | Market cache reports total debt of $13.8M. |
| SSII-DEBT-12755 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| SSII-OWNER-HOOD-RIVER-CAPITAL-MANAGEMENT-LL | Hood River Capital Management LLC | 90% | 13F overlay lists Hood River Capital Management LLC as top holder; 25 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ADGM | Adagio Medical Holdings, Inc. | 100.00 | 2 | |
| ATON | AlphaTON Capital Corp | 100.00 | 2 | |
| CLGN | CollPlant Biotechnologies Ltd. | 100.00 | 2 | |
| TRIB | Trinity Biotech plc | 100.00 | 2 | |
| ABBV | AbbVie Inc. | 100.00 | 2 | |
| AURA | Aura Biosciences, Inc. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 2 | |
| BCAX | Bicara Therapeutics Inc. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| ACIU | AC Immune SA | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| SNNUF | Smith & Nephew plc | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| ALC | Alcon Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| FDMT | 4D Molecular Therapeutics, Inc. | 100.00 | 2 |